Dyne Therapeutics Inc | 5.375% Series A Mandatory Convertible Preferred Stock (DYN.PRA)
Prospectus excerpt: Dividends on our Mandatory Convertible Preferred Stock will be payable on a cumulative basis when, as and if declared by our board of directors, at an annual rate of 5.375% on the liquidation preference of $100.00 per share. We may pay declared dividends in cash or, subject to certain limitations, in shares of common stock or by delivery of any combination of cash and shares of common stock on February 1, May 1, August 1 and November 1 of each year, commencing on February 1, 2015, and to, and including, November 1, 2017.
Dyne Therapeutics is a muscle disease company focused on developing therapeutics for people living with genetically driven diseases. Co. is developing the following product candidates: DYNE-101, to address the genetic basis of myotonic dystrophy type 1 by targeting the toxic nuclear DMPK RNA that causes the disease; DYNE-251 for patients with mutations amenable to skipping Exon 51, to be followed by the development of therapeutics for patients with mutations amenable to skipping other exons, including Exon 53, 45 and 44; and DYNE-301 to address the genetic basis of facioscapulohumeral dystrophy by reducing DUX4 expression in muscle tissue.